Señales en vivo de SCPS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:18):

Stats
Volumen de hoy	943.00
Volumen promedio	1 281.00
Capitalización de mercado	46 293.00
EPS	$-0.0658 ( 2023-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-23	Greenspan Ira Scott	Sell	3 000 000	W Warrants
2021-11-23	Lamstein Joshua R	Sell	3 000 000	W Warrants
2021-06-01	Hopper Paul	Buy	6 333	Common Stock
2020-12-15	Hopper Paul	Buy	0	Common Stock
2020-12-15	Hopper Paul	Sell	0	Common Stock

INSIDER POWER
0.00
Last 55 transactions
Buy: 2 180 518 \| Sell: 6 965 870

Scopus Biopharma Inc. Correlación

10 Correlaciones Más Positivas
KTTA	0.932
ISPO	0.915
UTME	0.91
SMIT	0.91
MTP	0.909
CREG	0.908
NCBS	0.906
HOL	0.905
NKTX	0.904
SWVL	0.902

10 Correlaciones Más Negativas
GDNR	-0.933
AMYT	-0.924
NWLI	-0.913
BRAC	-0.911
EMLD	-0.91
BTWN	-0.91
CDZI	-0.909
AVAC	-0.909
PROF	-0.908
EXAS	-0.908

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Scopus Biopharma Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.550

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.550

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.02

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Scopus Biopharma Inc.

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.